Journal of pediatric hematology/oncology
-
J. Pediatr. Hematol. Oncol. · Oct 2020
Obesity as a Potential Risk Factor for Vincristine-induced Peripheral Neuropathy.
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Vincristine is a core chemotherapeutic agent for patients with ALL; unfortunately, ∼78% will develop vincristine-induced peripheral neuropathy (VIPN). ⋯ We hypothesized that pediatric ALL patients who were obese at diagnosis would develop worse VIPN than healthy weight children with ALL within the first year. Our results confirmed that obese pediatric patients have significantly (P=0.03) worse VIPN than patients of healthy weight.